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Four  medical  therapies  previously  shown  to  exert  varying  degrees  of  protection  against
a convulsant  dose of  soman  were  assessed  for potential  behavioral  side  effects  in a
novelty  test.  In Experiment  1, HI-6  (1-[([4-(aminocarbonyl)pyridino]  methoxy)methyl]-2-
[(hydroxyimino)methyl]pyridinium)  (125 mg/kg),  scopolamine  (1 mg/kg),  physostigmine
(0.1  mg/kg),  levetiracetam  (50  mg/kg),  and  procyclidine  (20  mg/kg)  were  tested  sep-
arately.  In Experiment  2, the  combination  of  HI-6,  scopolamine,  and  physostigmine
(termed  the  physostigmine  regimen)  or HI-6, levetiracetam,  and  procyclidine  (termed  the
procyclidine  regimen)  were  tested.  In Experiment  3,  the metabotropic  glutamate  mod-
ulators  DCG-IV  ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine)  (4  mg/kg)  and  MPEP
(2-Methyl-6-(phenylethynyl)pyridine  hydrochloride)  (30  mg/kg)  were  tested  separately  or
each drug  in  combination  with  HI-6  and  procyclidine  (termed  the  DCG-IV  regimen  and  the
MPEP regimen,  respectively).  The  results  showed  that  the physostigmine  and  procyclidine
regimens  both  produced  severe  cognitive  impairment  (lack  of  preference  for novelty)  and
reduced locomotor  and  rearing  activities.  The  DCG-IV  and  MPEP  regimens  caused  milder
deﬁcits  on  the  same  behavioral  measures.  Some  relations  were  seen  between  prophylactic
capacity  and  degree  of  behavioral  side  effects.  Only  HI-6  or levetiracetam  had  no adverse
effects on  behavior.  DCG-IV  or MPEP  produced  some  impairment,  whereas  the  detrimen-
tal effects  of  scopolamine  or procyclidine  were  pronounced.  The  relatively  high dose  of
procyclidine  (anticholinergic  and  antiglutamatergic)  needed  for prophylactic  efﬁcacy  may
have played  a major  role for the  side  effects  of the regimens  in which  the  drug  was  used.  It
was concluded  that behavioral  side effects  are inevitable  for potent  prophylactic  therapies
against  soman  intoxication.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B
1. IntroductionExposure to nerve agent requires fast treatment with
antidotes, because such organophosphorus toxicant
causes dramatic enhancement of cholinergic activity in all
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bodily organs, most notably the central nervous system.
In  the brain, the cholinergic overstimulation rapidly
triggers excitotoxic glutamatergic activity accompanied
by seizures subsequently leading to death, because the
regulatory action of the respiratory center in the brainstem
is  interrupted by the high level of electrical discharges [1].
The  excessive cholinergic activity initiated by nerve agent
causes  irreversible inhibition of acetylcholinesterase, the
enzyme  that hydrolyzes acetylcholine.
In order to prevent lethality by nerve agent it is
important to shield temporarily a portion of the
is is an open access article under the CC BY-NC-ND license
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cetylcholinesterase from irreversible inhibition. Fol-
owing  exposure, therapeutic treatment with an
nticholinergic drug is supposed to be given. To meet these
equirements, a number of military forces have based their
edical  therapy on pyridostigmine pretreatment to pre-
ent  acetylcholine inhibition by nerve agents followed by
he  immediate therapeutic treatment with atropine sulfate
nd  an oxime administered by one or more autoinjectors.
hese drugs are intended to inhibit muscarinic receptors
nd  to reactivate any “unaged” enzyme, respectively,
ollowing exposure to nerve agent [2]. However, inasmuch
s  pyridostigmine does not readily cross the blood-brain
arrier, physostigmine that readily enters the brain, has
een  suggested as a possible replacement. In studies of
uinea  pigs and rats, evidence has been presented that
ffective prevention of soman-induced lethality can be
nsured  by physostigmine in combination with scopol-
mine or procyclidine [3–7]. Pyridostigmine combined
ith caramiphen or benactyzine and trihexyphenidyl
r with biperiden have also been reported to provide
fﬁcacious pretreatment in soman-poisoned rats [8–10].
Two  medical therapies consisting of HI-6 (1-[([4-(amin-
carbonyl)pyridino] methoxy)methyl]-2-[(hydroxyimino)
ethyl]pyridinium), scopolamine, and physostigmine
termed the physostigmine regimen) or HI-6, leve-
iracetam, and procyclidine (termed the procyclidine
egimen) have been shown to be very effective 1 min
fter high levels of soman poisoning, but they differ
arkedly in anticonvulsant capacity when administered
0 or 20 min  after soman exposure. However, when
iven 20 min  before soman intoxication, both regimens
xert very effective protection [11]. Furthermore, in a
tudy  of the metabotropic glutamate modulators DCG-
V  ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine) and
PEP  (2-Methyl-6-(phenylethynyl)pyridine hydrochlo-
ide) it was demonstrated that treatment regimens
onsisting of HI-6, procyclidine, and DCG-IV (termed the
CG-IV  regimen) or HI-6, procyclidine, and MPEP (termed
he  MPEP regimen) both have substantial antidotal efﬁcacy
hen  administered 20 min  after onset of soman-induced
eizures. When given 20 min  before challenge with soman,
he  DCG-IV regimen provides good protection, whereas the
PEP  regimen has weaker antidotal impact [12]. In the
resent  study, it was of interest to examine whether the
egree  of protective potency of the various regimens may
e  related to the degree of potential behavioral side effects
roduced by the regimens.
Because  seizures are associated with both lethality
nd brain damage [13], it is very important to prevent
he onset of seizures or terminate seizures within 20 min
fter  onset to avoid neuropathology [14,15]. However,
 crucial matter is whether the doses of prophylactics
equired for protection of military personnel against nerve
gent-induced damage will impair cognitive functions. The
urpose  of the present study was to make a comparative
ssessment of potential behavioral effects of HI-6, sco-
olamine, physostigmine, levetiracetam, and procyclidine
eparately (Experiment 1), the combinations of HI-6, sco-
olamine, and physostigmine or HI-6, levetiracetam, and
rocyclidine (Experiment 2), DGC-IV and MPEP separately
r  each drug in combination with HI-6 and procyclidineorts 1 (2014) 102–113 103
(Experiment 3). The doses of drugs chosen have previ-
ously been shown to have anticonvulsant effects against
soman-induced seizures. The behavioral task employed
was a novelty test that has proven particularly sensitive
in  revealing cognitive dysfunctions following selective
disruptions of entorhinal projections [16,17]. Exploration
of  a discrete novel object is one form of inquisitive activity
frequently seen among rats. This activity appears as a
strong  preference for novelty, the recognition of which is
probably  based on polymodal sensory information [18].
The  rats were tested in a modiﬁed version of the novelty
test of Berlyne [19] consisting of three different sets of
stimuli: visual/tactile, olfactory, or visual only [16].
2.  Materials and methods
2.1.  Animals
2.1.1. Experiment 1
Forty-eight  male Wistar albino rats from a commer-
cial supplier (Taconic Breeding Laboratories, Denmark)
weighing 280–310 g when the experiment started, served
as  subjects. The rats were randomly assigned to one of
the  6 groups (8 rats in each) and their group assignment
was unknown during testing. The various groups received
either  saline, HI-6, scopolamine, physostigmine, levetirac-
etam, or procyclidine. The rats were housed individually
and had free access to commercial rat pellets and water.
With the novelty test used, reliable results are dependent
on emotionally stable animals. For this reason, the rats were
handled  individually 7–10 days, being allowed to explore
a  table top (80 cm × 60 cm)  for 3 min  a day. The climatized
(21 ◦C) vivarium was  illuminated from 0700 to 1900 h.
2.1.2.  Experiment 2
Twenty-four  male Wistar rats (280–310 g) from the
same supplier served as subjects. The animals were ran-
domly  assigned to one of the 3 groups with 8 rats in each.
The  various groups received saline, the combination of HI-
6,  scopolamine, and physostigmine or the combination of
HI-6,  levetiracetam, and procyclidine. The rats were treated
as  described for Experiment 1.
2.1.3. Experiment 3
Forty  male Wistar rats (280–310 g) from the same
supplier served as subjects. The animals were randomly
assigned to 5 groups with 8 rats in each. The various groups
received saline, DCG-IV, MPEP, or the combinations of HI-6,
procyclidine, and DCG-IV or HI-6, procyclidine, and MPEP.
The  rats were treated as described for Experiment 1.
The  experiments were approved by the National Animal
Research Authority. A minimal number of animals were
used,  and all efforts were made to avoid animal suffer-
ing according to The Code of Ethics of the World Medical
Association and the EU Directive 2010/63/EU.
2.2. Drug administrationThe  drug doses chosen for Experiment 1 and 2
were derived from previous studies of anticonvulsant
effects against soman-evoked seizures in rats: HI-6
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Table 1
Mean  (±SEM) measures of exploratory behavior in seconds in novelty test in Experiment 1. Differential time exploring is the difference between exploring
novel  and neutral items.
Group N Dose
mg/kg
Differential time exploring Total time exploring
Session  Session
I II III I II III
Phase 2 Phase 2 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2
Saline 8 – 8.5 ± 2.1 21.2 ± 4.0 15.4 ± 2.2 13.8 ± 1.9 14.1 ± 5.7 16.4 ± 1.7 34.1 ± 8.3 13.4 ± 2.8 21.3 ± 3.9
HI-6  8 125 8.3 ± 2.2 19.1 ± 3.6 13.9 ± 3.0 23.8 ± 3.0 23.1 ± 3.6 17.8 ± 2.3 35.3 ± 3.6 28.5 ± 4.5 b 25.8 ± 4.1
Scopolamine  8 1 0.5 ± 0.3a 2.6 ± 0.5b 1.2 ± 0.8c 12.4 ± 2.3 10.0 ± 2.5 3.1 ± 1.1b 4.3 ± 2.1c 1.5 ± 0.4a 6.1 ± 2.0b
Physostigmine 8 0.1 4.8 ± 1.5 17.5 ± 3.6 16.3 ± 3.1 17.8 ± 2.3 9.4 ± 1.9 16.4 ± 3.5 20.3 ± 3.3 19.1 ± 4.5 23.0 ± 3.6
Levetiracetam  8 50 7.8 ± 2.4 23.9 ± 5.4 10.6 ± 2.2 16.4 ± 3.8 15.8 ± 4.3 12.1 ± 3.3 26.9 ± 5.4 14.5 ± 2.1 17.0 ± 2.4
Procyclidine  8 20 1.2 ± 0.4a 3.7 ± 1.4b 2.8 ± 0.5b 15.0 ± 2.6 8.3 ± 2.6 12.0 ± 3.4 8.9 ± 1.9b 3.1 ± 1.7a 4.7 ± 0.8b
Signiﬁcantly different from the saline group:
a p < 0.05,
b p < 0.01,
c p < 0.001.
dimethanesulfonate 125 mg/kg, scopolamine hydrobro-
mide 1 mg/kg, physostigmine salicylate 0.1 mg/kg, leve-
tiracetam (Keppra®) 50 mg/kg, procyclidine hydrochloride
20 mg/kg [11,20–22]. The drugs chosen for Experiment 3
were  based on a previous study of anticonvulsant effects:
DCG-IV 4 mg/kg and MPEP 30 mg/kg [12]. The doses of
HI-6  and procyclidine were the same as for Experiment
1 and 2. The drugs were dissolved in 0.9% saline. MPEP
was  dissolved in isotonic saline at a concentration of
5  mg/ml. All drugs were administered intraperitoneally
(i.p.). The drugs were given 20 min  before each test ses-
sion  (one session a day for 3 days) with a total testing
period of 20 min. When combinations were made, the
injections were given in rapid succession according to the
sequences  of drugs presented in Tables 3 and 5. Phys-
iological saline was injected i.p. in a volume of 0.3 ml.
Prophylactics are usually given 20 or 30 min  before expo-
sure  to nerve agent [23]. Scopolamine, physostigmine, and
procyclidine were purchased from Sigma (St Louis, MO,
USA).  DCG-IV and MPEP were purchased from Tocris Cook-
son  Ltd (Bristol, UK), and HI-6 DMS  was a generous gift from
Defence  Research and Development (Sufﬁeld, Medicine
Hat, Canada). Levetiracetam is commercially available as
Keppra®.
2.3.  Apparatus
Behavioral testing was carried out in a Plexiglas cage
(54  cm × 33 cm × 20 cm)  previously described [16]. In brief,
the  ﬂoor was divided in 18 equal squares (9 cm × 11 cm).
Three  identical aluminum cubes (5 cm × 5 cm × 5 cm)  were
evenly distributed in the cage in ﬁxed positions (the neu-
tral  objects). Three other cubes made up the novel objects.
One  object only differed from the neutral ones in that
its  top was uneven with tracks (2 mm)  in it making up a
square  pattern (visual/tactile stimuli). Since the rats could
perceive  the tracks or the squares (16 squares measuring
1.1 cm × 1.1 cm)  by bodily contact, both tactile and visual
sensory modalities might be used. One was identical with
the  neutral ones, and a spot of cheese (dia. 1.5 cm)  was
smeared on the side facing the experimenter (olfactory
stimulus). So-called Norwegian white cheese (Norvegia)that  hardly smells at all to humans was used. In the test
cage,  it was  not possible to detect the cheese visually. One
was  smaller than the neutrals (4.5 cm × 4.5 cm × 4.5 cm)
and  two  sides were slightly uneven (visual stimulus). All
objects  were painted light gray. The sound attenuated test-
ing  room was provided with a fan producing white noise
(52  dB).
2.4.  Procedure
The same procedure was  followed for Experiments 1, 2
and  3. During adaptation, the rats were allowed to explore
individually the empty apparatus for 20 min. On the next
day,  the rats were given the test drugs before they were run
in  Session I. In Phase 1, the animals were tested for 5 min
in  the test cage with three neutral objects present. Then
the  rats spent 10 min  in the home cage. In Phase 2, the rats
were  tested again for 5 min, and the neutral object in the
middle  position had been replaced by the novel object with
uneven  top. Changing position of neutral object makes up
a  novelty in itself [24]. Preference for novelty was based on
the  difference between exploration of novel versus neu-
tral  objects, and the mean time of contact with the two
neutral objects was used. During Phases 1 and 2 the follow-
ing  behaviors were recorded: number of seconds in contact
with  the objects, number of squares traversed (locomotor
activity), and number of rearings. Exploration of an object
was  deﬁned as directing the snout toward the object at a
distance  of 1.5 cm or less. Bodily touch other than by the
snout  was  not considered as exploratory behavior. Prior to
testing  of each rat the apparatus and objects were care-
fully  washed with Zalo (Lilleborg, Norway) dissolved in
water  and allowed to dry. In Sessions II and III (test days
2  and 3), the same procedure was  followed, and the nov-
elty  was represented by smell of cheese on one side of
the  cube and a smaller object, respectively. Since changing
the  order of novelty presentation can lead to different pat-
terns  of locomotor and rearing activity, a counterbalanced
order of testing was not used to control for accumulative
effects of drugs on activity measures. The same set of neu-
tral  cubes was  used after olfactory cues had properly been
eliminated. One observer, who  was  unaware of the rats’
logy Reports 1 (2014) 102–113 105
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roup assignment, recorded the data manually without TV
onitoring.
.5.  Statistics
Overall analyses were carried out with one-way or two-
ay  analysis of variance (ANOVA). Group comparisons
ere made with Newman–Keuls post hoc test. Computa-
ions were made with Prism statistical software program
GraphPad Software, CA, USA).
. Results
.1. Experiment 1
In  Tables 1 and 2, signiﬁcant differences relative to the
aline  group are presented. Only signiﬁcant differences
mong the various treatment groups are presented in this
ection.  In Session I, both the scopolamine and procyclidine
roups displayed signiﬁcantly lower preference for nov-
lty  than the HI-6 and levetiracetam groups (P < 0.05). In
essions  II and III, both the scopolamine and procyclidine
roups displayed signiﬁcantly lower preference for novelty
han  the HI-6, physostigmine, and levetiracetam groups
P  < 0.05). The total time exploring objects did not differ sig-
iﬁcantly  among the groups for Phases 1 and 2 in Session
 (F(5,42) = 2.184, P > 0.05; F(5,42) = 2.292, P > 0.05, respec-
ively). In Phase 1 in Session II, the scopolamine group
xplored the novel object reliably less than the HI-6 and
hysostigmine groups (P < 0.05). In Phase 2 in Session II, the
copolamine group had signiﬁcant lower exploring time
han  the HI-6, physostigmine, and levetiracetam groups
P  < 0.05) and the procyclidine group had reliably lower
xploring time than the HI-6 and levetiracetam groups
P  < 0.05). In Phases 1 and 2 in Session III, the scopolamine
nd procyclidine groups displayed signiﬁcantly less explor-
ng  than the HI-6, physostigmine, and levetiracetam groups
P  < 0.05).
As seen from Table 2, rats treated with scopolamine,
hysostigmine, or procyclidine tended to display less
otor activity than the control animals. Two-way ANOVA
evealed a signiﬁcant Group × Time (Session/Phase) inter-
ction  (F(25,252) = 4.784, P = 0.0001), a signiﬁcant between
roup  factor (F(5,50) = 43.29, P < 0.0001), as well as a sig-
iﬁcant  within group factor (F(5,252) = 20.55, P < 0.0001).
n  Phase 2 in Session I, the physostigmine and procycli-
ine groups were signiﬁcantly less active than the HI-6
nd  levetiracetam groups (P < 0.01). In Phase 1 in Session II,
he  scopolamine, physostigmine, and procyclidine groups
ere  reliably less active than the HI-6 and levetiracetam
roups (P < 0.01). In Phase 2 in Session II, the procyclidine
roup displayed signiﬁcantly less motor activity than the
I-6,  physostigmine, and levetiracetam groups (P < 0.01). In
hase  1 in Session III, the scopolamine, physostigmine, and
rocyclidine groups were reliably less active than the HI-6
nd  levetiracetam groups (P < 0.001). In Phase 2 in Session
II,  the scopolamine and procyclidine groups were reliably
ess  active than the HI-6 and levetiracetam groups (P < 0.01)
nd  the physostigmine group was signiﬁcantly less active
han  the levetiracetam group (P < 0.05). Ta
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Table 3
Mean (±SEM) measures of exploratory behavior in seconds in novelty test in Experiment 2. Differential time exploring is the difference between exploring novel and
neutral  items.
Signiﬁcantly different from the saline group:
ap < 0.05,
bp < 0.01,
cp < 0.001.
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The rearing activity also differed among the groups
(Table 2). Two-way ANOVA revealed a signiﬁcant between
group factor (F(5,50) = 44.10, P < 0.0001), as well as a sig-
niﬁcant  within group factor (F(5,252) = 6.955, P < 0.0001),
but  not a Group × Time (Session/Phase) interaction
(F(25,252) = 1.423, P = 0.0924). In Phase 1 in Session I, the
procyclidine group made signiﬁcantly less rearing than
the  HI-6 and levetiracetam groups (P < 0.05). In Phase 2 in
Session  I, the procyclidine group made reliably less rear-
ing  than the HI-6, scopolamine, and levetiracetam groups
(P  < 0.01). In Phase 1 in Session II, the procyclidine group
made less rearing than the HI-6, scopolamine, physostig-
mine, and levetiracetam groups (P < 0.01). The scopolamine
and physostigmine groups made signiﬁcantly less rearing
than  the HI-6 and levetiracetam groups (P < 0.05). In Phase 2
in  Session II, the procyclidine group made less rearing than
the  HI-6, scopolamine, physostigmine, and levetiracetam
groups (P < 0.05). In Phase 1 in Session III, the procyclidine
group made less rearing than the HI-6, scopolamine, and
levetiracetam groups (P < 0.01). The physostigmine group
made  less rearing than the HI-6, scopolamine, and leve-
tiracetam groups (P < 0.01). In Phase 2 in Session III, the
procyclidine group made less rearing than the HI-6, sco-
polamine, and levetiracetam groups (P < 0.05).
3.2. Experiment 2
All  signiﬁcant differences found between the treat-
ments are presented in Tables 3 and 4. Both the physostig-
mine and procyclidine regimens caused decreased locomo-
tor  activity (Table 4). Two-way ANOVA revealed a signiﬁ-
cant  between group factor (F(2,25) = 101.2, P < 0.0001), as
well  as a signiﬁcant within group factor (F(5,126) = 12.07,
P  < 0.0001), but not a Group × Time (Session/Phase) inter-
action (F(10,126) = 0.4996, P > 0.05). The physostigmine
and procyclidine regimens also reduced the num-
ber of rearings (Table 4). Two-way ANOVA revealed
a signiﬁcant Group × Time (Session/Phase) interaction
(F(10,126) = 2.048, P = 0.0336), a signiﬁcant between group
factor  (F(2,25) = 94.00, P < 0.0001), as well as a signiﬁcant
within group factor (F(5,126) = 4.838, P = 0.0004).
3.3.  Experiment 3
Decreased  preference for novelty was  seen in several
groups (Table 5). In Session II, both the DCG-IV and MPEP
regimens displayed less preference than DCG-IV (P < 0.05).
In  Session III, both treatment regimens caused less prefer-
ence  for novelty than the MPEP (P < 0.01). The total time
exploring differed somewhat among the groups. In Phase
2  in Session III, the DCG-IV regimen caused less exploring
than MPEP (P < 0.05).
Reduced locomotor activity was seen among the
groups (Table 6). Two-way ANOVA revealed a signiﬁ-
cant between group factor (F(4,42) = 38.62, P < 0.0001), as
well  as a signiﬁcant within group factor (F(5,210) = 7.717,
P  < 0.0001), but not a Group × Time (Session/Phase) inter-
action (F(20,210) = 1.006, P > 0.05). Some signiﬁcant differ-
ences  between the treatment groups were found. In Phase
1  in Session II, the DCG-IV regimen produced less locomo-
tion  than DCG-IV and MPEP (P < 0.05). The MPEP regimen
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Table 5
Mean (±SEM) measures of exploratory behavior in seconds in novelty test in Experiment 3. Differential time exploring is the difference between exploring novel and
neutral  items.
Signiﬁcantly different from the saline group:
ap < 0.05,
bp < 0.01,
cp < 0.001.
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Table 6
Mean (±SEM) measures of locomotor (squares) and rearing activity in novelty test in Experiment 3.
Doses and number of animals as in Table 5. Signiﬁcantly different from the saline group:
ap < 0.05,
bp < 0.01,
cp < 0.001.
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caused less locomotion than DCG-IV (P < 0.001). The DCG-
IV  and MPEP regimens resulted in less locomotor activity
than  DCG-IV and MPEP (P < 0.05). In Phase 1 in Session III,
the  DCG-IV regimen produced less locomotion DCG-IV and
MPEP  (P < 0.05). In Phase 2 in Session III, the DCG-IV regi-
men  produced less locomotion DCG-IV and MPEP (P < 0.05).
The  rearing activity also differed among the groups
(Table 6). Two-way ANOVA revealed a signiﬁcant between
group  factor (F(4,42) = 35.98, P < 0.0001), as well as a sig-
niﬁcant  within group factor (F(5,210) = 4.061, P = 0.0015),
but  not a Group × Time (Session/Phase) interaction
(F(20,210) = 1.115, P > 0.05). In Phase 1 in Session II, the
DCG-IV and MPEP regimens resulted in less rearing activity
than  DCG-IV and MPEP (P < 0.05). In Phase 2 in Session II,
the  DCG-IV and MPEP regimens caused less rearing activ-
ity  than DCG-IV and MPEP (P < 0.05). In Phase 1 in Session
III,  the DCG-IV regimen produced less rearing than DCG-IV
and  MPEP (P < 0.05). In Phase 1 in Session III, the DCG-IV
and MPEP regimens resulted in less rearing activity than
DCG-IV  and MPEP (P < 0.05).
4.  Discussion
The results from the present study clearly showed
that the prophylactic regimens tested can have marked
cognitive side effects. The preference for novelty was  abol-
ished  by the physostigmine and procyclidine regimens
and reduced by the DCG-IV and MPEP regimens (Table 7).
Scopolamine and procyclidine separately impaired prefer-
ence  for novelty pronouncedly, whereas MPEP exerted a
slight  adverse effect. HI-6, physostigmine, levetiracetam,
and DCG-IV alone did not cause cognitive deﬁcits. Locomo-
tor  and rearing activities did not differ much between the
various  regimens, but large differences were seen between
the  single drugs.
Some  relations between the degree of cognitive per-
formance and prophylactic capacities can be seen for the
regimens. The most efﬁcient protection is obtained by
the  physostigmine and procyclidine regimens, whereas
the  DCG-IV and MPEP regimens have weaker prophylac-
tic capacities [11,12]. The total time exploring, reﬂecting
the  interest in the environment, was less reduced in the
rats  given the DCG-IV or MPEP regimens than the rats that
received  the physostigmine or procyclidine regimens. On
the  other hand, all 4 regimens made the rats very inactive
as  a marked decrement in locomotor and rearing activities
was  measured.
When combining a cholinesterase inhibitor like
physostigmine and an anticholinergic like scopolamine
equalizing effects are expected to occur [3]. In view of
the  present results, this was not the case for cognitive
performance or activity measures. A potential explanation
of  the adverse effects might be that continuous stimulation
of  acetylcholine receptors resulted in desensitization and
enhanced  efﬁcacy of anticholinergic drugs. If procyclidine
is  used in lower doses (1 and 3 mg/kg) in combination with
physostigmine (0.1 mg/kg), much milder interference with
behavioral  functions are seen in the present novelty task
[25].
Scopolamine has indisputable detrimental effect on the
performance of rats in water maze, radial maze, passiveorts 1 (2014) 102–113
avoidance, and spontaneous alternation [26]. In behav-
ioral  studies, the dose of scopolamine commonly used is
0.5  mg/kg [27]. However, scopolamine has been reported to
impair  performance in delayed matching to position tasks
at  doses as low as 0.05 and 0.075 mg/kg in rats [28,29].
It has been reported that general locomotor activity can
be  depressed following administration of acetylcholiner-
sterase inhibitors such as physostigmine [30]. In contrast,
classical acetylcholine receptor antagonists like scopol-
amine and atropine generally increase measures of activity
in  many species, including the rat [31,32]. In the present
study, scopolamine and physostigmine tended to reduce
both  locomotor and rearing activity.
HI-6 and levetiracetam had no negative effects on
any of the behavioral measures used. Procyclidine at a
dose  of 20 mg/kg impaired all aspects of behavior in the
novelty test. Hence, the pronounced impairment of the
procyclidine regimen is most likely attributable to the rel-
atively  high dose of procyclidine that is required for the
procyclidine regimen to become effective against soman-
induced seizures [11]. Procyclidine at a dose of 3 mg/kg is
without  effects in the novelty test, whereas 6 mg/kg has
adverse effects [25]. Relatively low doses of procyclidine
(1, 3, 6 mg/kg) are sufﬁcient when this drug is combined
with physostigmine (0.1 mg/kg) to protect against convul-
sant  doses of soman (1.3×, 1.6×, 2.0× LD50, respectively)
[5].
HI-6 (125 mg/kg) did not produce any adverse behav-
ioral effects in the present test. This ﬁnding corresponds
well with previous results from rats. Only doses above
125  mg/kg of HI-6 have adverse effects on open ﬁeld activ-
ity,  motor coordination, or shuttle-box performance [33].
HI-6  at the highest dose used (100 mg/kg) disrupts operant
ﬁxed  ratio responding, but not performances in shuttle-
box, drinking motivation, exploratory behavior, negative
geotaxis, or suspension time [34]. Furthermore, HI-6 at a
dose  above 154 mg/kg results in impairment of an operant
task  using a variable-interval 56 s schedule of food rein-
forcement [35].
Levetiracetam (50 mg/kg) had no effect on the param-
eters used in the novelty task. Absence of negative impact
on  behavior has been reported for even high doses of leve-
tiracetam in rats. Levetiracetam up to 170 mg/kg does not
impair  the performance in water maze [36]. Levetiracetam
at doses up to 200 mg/kg have no detrimental efﬁcacy on
operant  ﬁve-choice serial reaction task or operant repeated
acquisition of response sequences task [37,38].
A high dose of procyclidine (20 mg/kg) can affect sev-
eral  aspects of behavior as seen from the present study.
Procyclidine in a dose range of 0.1–5.6 does not impair
acoustic startle response in rats [39]. A dose of 1 mg/kg of
procyclidine does not attenuate performance in an operant
conditioning task, whereas impairment is seen after a dose
of  10 mg/kg [40].
To our knowledge, no study has examined behavioral
effects of systemic administration of DCG-IV in rats. There
is,  however, one study of mice showing that DCG-IV (5
or  10 mg/kg) reduces locomotor activity in a test appara-
tus  [41]. This ﬁnding coincides with our results that the
only  impact of DCG-IV (4 mg/kg) was  a moderate decline
in  locomotion.
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Table 7
Preference for novelty relative to saline-treated rats.
↓, decreased; –, unchanged.
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MPEP (10 mg/kg) has been shown to impair response
rate, but not response accuracy in operant repeated acqui-
sition,  whereas spatial memory in radial maze is not
affected [42]. MPEP at 3 or 10 mg/kg does not inter-
fere with locomotor activity, whereas only the highest
dose decreases performance in spontaneous alternation
and operant learning [43]. Furthermore, MPEP (3, 6, or
12  mg/kg) causes detrimental effects on latent inhibition
in  conditioned taste aversion in a dose-dependent man-
ner  [44]. However, MPEP at a dose of 30 mg/kg does not
affect  rotarod locomotor performance in rats [45]. Hence,
it  was not surprising that our relatively high MPEP dose
(30  mg/kg) produced a moderate cognitive deﬁcit and also
affected  locomotor activity and barely inﬂuenced rearing
activity.
Of  the single drugs tested, scopolamine and procyclidine
produced severe cognitive deﬁcits. Scopolamine attenu-
ates  normal cholinergic activity that is a prerequisite for
normal  attention processes [46]. Since the scopolamine
group also tended to display less total time exploring, these
rats  might have paid less attention to the surroundings
as well as the objects. The rats that received procycli-
dine behaved in a similar way showing both cognitive
deﬁcit and reduced total time exploring. In addition to
cholinergic antagonism, procyclidine also exerts NMDA
antagonism [47,48]. Thus, impairment of working mem-
ory  (contemporary comparing objects) as well as reference
memory (preserving information from Phase 1 to Phase
2)  may  have contributed to the present results. It can-
not  be excluded, however, that a non-cognitive factor like
motor  dysfunction may  be associated with the behavioral
changes.
In  order to ensure complete protection against a con-
vulsant dose of soman, comprehensive interference with
the  central nervous system is required. Thus, from a the-
oretical  point of view, behavioral side effects will likely
occur. The physostigmine and procyclidine regimens that
produce  complete protection against lethal doses of soman
[11]  caused the most severe side effects in the present
study. If partial protection followed by adjunct treatment
after exposure to nerve agent is acceptable, pretreatment
with HI-6 and levetiracetam accompanied by procyclidine
might be an option. HI-6 and levetiracetam were without
behavioral side effects in the present study. The potent
anticonvulsant procyclidine (anticholinergic and antiglu-
tamatergic) is more appropriately used as a post-poisoning
drug than as a prophylactic agent. The potency of HI-6
and  levetiracetam used as prophylactics followed by pro-
cyclidine  as adjunct has partly been tested before. Rats
pretreated with HI-6 that were about to die 5–10 min  after
onset  of soman-induced seizures survived and recovered
well when they were treated with levetiracetam and pro-
cyclidine  [21].
In  conclusion, prophylactic regimens previously
demonstrated to effectively protect against lethal doses
of  soman exert adverse effects on behavior. To circumvent
the problem drugs with antidotal efﬁcacy, but with-
out behavioral side effects (HI-6, levetiracetam) may
be  used as prophylactics followed by a more powerful
adjunct therapy (procyclidine) after challenge with nerve
agent.
[orts 1 (2014) 102–113
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